期刊文献+

羧肽酶A1及其活性中心基因的表达及活性分析 被引量:3

The Expression of Human Carboxypeptidase Al and Its Active Center Gene
下载PDF
导出
摘要 目的:克隆羧肽酶A1(carboxypeptidase A1,CPA1)全酶及其活性中心基因,构建重组表达载体进行诱导表达,分析表达产物活性。方法:RT-PCR扩增CPA1全酶及活性中心基因,测序分析后将目的基因克隆于表达载体pGEX-4T-1,测序证实插入方向正确后转化大肠杆菌BL21,IPTG诱导表达目的基因后SDS-PAGE电泳分析。目的蛋白经变性、复性、纯化后MTT 法和集落形成试验鉴定其活性。结果:获得了人CPA1全酶及活性中心基因,目的基因诱导表达后约66 kD及46 kD处可见新生蛋白带;活性分析显示CPA1全酶和活性中心蛋白都具有一定的催化水解活性,但后者对肿瘤细胞的杀伤效果较弱。结论:能成功克隆了人CPA1全酶及其活性中心基因,获得了二者的原核表达产物,体外具有一定活性。可望以人羧肽酶A1全酶及其活性中心基因为新起点,继续完善优化羧肽酶A1系统,为抗体靶向治疗前列腺癌的临床应用奠定基础。 Objective: To clone human carboxypeptidase A1 and its active center gene as well as construct recombinant vector for expression before analysis their activities. Methods: CPA1 and CPA1active cester gene were amplified by RT-PCR from pancreas tissue, and then sequencing was carried out. The correct target genes were cloned into prokaryotic vector pGEX-4T-1 and transformed into E. coli BL21 before sequence analysis. After induced by IPTG, gene products were analyzed by SDS-PAGE. Target expressed proteins were denaturated, renaturated, purified and evaluated through MTT and agar colony form test. Results: Human carboxypeptidase A1 and its active center gene were cloned successfully. New expected protein band of Mr 66,000 and 46,000 appeared on SDS-PAGE after inducement. Both of the expressed proteins have catalytic activity in vitro, but the activity of the latter is inferior when applied to tumor cells. Conclusions: Human carboxypeptidase A1 and its active center gene were cloned successfully. Their prokaryotic expression products were obtained too. The expressed proteins have catalytic activity in vitro. A new prosperous beginning of further improvement for CPA1 therapy system has been established based on CPA1 and its active center gene in terms of ADEPT against prostate cancer to clinical application.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2005年第3期206-210,共5页 Chinese Journal of Cancer Biotherapy
基金 国家十五重大科技专项(2002AA223109)国家863项目2001AA21532
关键词 羧肽酶A1 活性中心 原核表达 活性分析 carboxypeptidase A1 active center prokaryotic expression catalytic activity
  • 相关文献

参考文献6

  • 1Francis R J, Sharma SK, Springer C, et al. A phase I trial of antibody directed enzyme predrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours[J]. BrJ Cancer, 2002, 87(6): 600-607.
  • 2Haisma HJ, Sernee MF, Hooijberg E, et al. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibedy-directed enzyme prodrug therapy[ J]. Blood, 1998, 92( 1 ): 184-190.
  • 3Vrudhula VM, Kerr DE, Siemers NO, et al. Cephalo sporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-Lactamase fusion protein [ J ]. Bioorg Med Chem Lett,2003,13(3):539-542.
  • 4郝晓柯,施溥涛,张盈华,殷缨,韩云龙.前体药物甲氨喋呤-α-肽对前列腺癌动物模型治疗的研究[J].中国肿瘤生物治疗杂志,2000,7(3):195-198. 被引量:3
  • 5Wei S, Segura S, Vendrell J, et al. Identification and characterization of three members of the human metallocar- boxypeptidase gene family[J]. J Biol Chem, 2002, 17(277): 14954-14964.
  • 6Winter J, Lilie H, Rudolph R. Renaturation of human proinsulin-a study on refolding and conversion to insulin[J]. Anal Biochem, 2002, 310(2): 148-155.

二级参考文献5

共引文献2

同被引文献20

  • 1易静,郝晓柯,苏明权,岳乔红,刘家云,张瑞,雷迎峰.人羧肽酶A1活性中心的毕赤酵母可溶表达[J].第四军医大学学报,2006,27(5):389-391. 被引量:5
  • 2Francis RJ, Sharma SK, Springer C, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer, 2002,87:600-607.
  • 3Mayer A, Francis RJ, Sharma SK, et al. A phase I study of single administration of antlbody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibodyenzyme fusion protein MFECPI and a bis-iodo phenol mustard prodrug. Clin Cancer Res, 2006,12:6509-6516.
  • 4Coelho V, Dernedde J, Petrauseh U, et al. Design, construction, and in vitro analysis of A33scFv: CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. Int J Oncol, 2007,31:951-957.
  • 5Hao XK, Liu JY, Yue QH, et al. In vitro and in vivo prodrug therapy of prostate cancer using anti~gamma-Sm-scFv/hCPA fusion protein. Prostate, 2006,66:858-866.
  • 6Wei S, Segura S, Vendrell J, et al. Identification and characterization of three mealbers of the human metallocarboxypeptidase gene family. J Biol Chem, 2002,277 : 14954-14964.
  • 7Bagshawe K D. Antibody-directed enzymes revive anti-cancer pro drugs concept[J]. Br J Cancer, 1987, 56(5) :531-532.
  • 8Sharma S K, Bagshawe K D, Begent R H. Advances in antibody-directed enzyme prodrug therapy [J]. Curr Opin Investig Drugs, 2005, 6(6) :611-615.
  • 9Hao X K, Liu J Y, Yue Q H, et al. In vitro and in vivo prodrug therapy of prostate cancer using anti-γ-Sm-scFv/hCPA fusion protein[J]. Prostate, 2006,66(8) :858-866.
  • 10Perron M J, Page M. Activation of methotrexate phenytataninely monoclonal antibody-canboxypentidase A conjugate for the specific treatment of ovarian cancer in vitro[J]. Br J Cancer, 1996, 73(3) :781-287.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部